---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-007221"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:07:19.418295+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics shareholders approve reverse stock split range of 1:5 to 1:30

## Summary
- Proposal 1 passed with ~90.8% of votes cast in favor (27.6M for, 2.5M against, 0.3M abstain).
- Proposal 2 (adjournment) also approved with ~91.5% of votes cast in favor (27.7M for).
- Board retains discretion to select exact split ratio between 1:5 and 1:30 at a later date.
- Approximately 61.2% of outstanding common stock (30.4M shares) was represented at the special meeting.

## SEC filing metadata
- accession: 0001104659-25-007221
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925007221/0001104659-25-007221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925007221/tm254832d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-007221
- JSON: https://secwatch.observer/filing/0001104659-25-007221.json
- Plain text: https://secwatch.observer/filing/0001104659-25-007221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.